Baxter International (BAX) Research

Forward Estimates

EPS Estimates

Current Qtr

$0.37

$0.36$0.39

vs $0.59-37.6%

11 analysts

Next Qtr

$0.53

$0.43$0.59

vs $0.69-22.9%

11 analysts

Current Yr

$1.92

$1.85$1.96

vs $2.27-15.6%

13 analysts

Next Yr

$2.02

$1.87$2.45

vs $1.92+5.2%

14 analysts

Revenue Estimates

Current Qtr

$2.80B

$2.77B$2.85B

vs $2.81B-0.4%

11 analysts

Next Qtr

$2.86B

$2.81B$2.89B

vs $2.83B+0.8%

11 analysts

Current Yr

$11.36B

$11.33B$11.43B

vs $11.24B+1.0%

13 analysts

Next Yr

$11.58B

$11.44B$11.77B

vs $11.36B+2.0%

13 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for BAX on EDGAR.

BAX filing events and research context
Filed	Item	Context
Feb 12, 2026	business	Baxter International Inc. provides essential healthcare products across three reportable segments: Medical Products & Therapies (sterile IV solutions, infusion systems, and parenteral nutrition), Healthcare Systems & Technologies (smart bed systems, patient monitoring, and respiratory devices), and Pharmaceuticals (specialty injectables and inhaled anesthetics). The company is currently executing a rigorous portfolio optimization and deleveraging strategy, evidenced by the divestitures of its BioPharma Solutions and Kidney Care businesses. Proceeds from these transactions were primarily used to retire legacy debt, as Baxter targets a net leverage ratio of approximately 3.0x by the end of 2026. To support this financial discipline, the company has reduced its dividend and suspended share repurchases. Strategically, Baxter is shifting toward "connected care" by integrating software and digital analytics into its device portfolio to improve patient outcomes. Operationally, the company has implemented a new operating model to streamline manufacturing and supply chains, reducing managerial layers and exploring AI-driven automation to increase efficiency. Baxter maintains a global footprint, selling in over 100 countries through direct sales and third-party distributors including Cardinal Health and Medline.
Feb 12, 2026	mda	Baxter faces potential material impairments to goodwill and intangible assets, particularly following the 2021 Hillrom acquisition. Revenue is heavily dependent on contracts with Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs), which often restrict pricing and include "failure to supply" penalties. Supply chain vulnerabilities persist due to reliance on sole-source providers for resins, electromechanical components, and active pharmaceutical ingredients. Operational risks include complex biologics manufacturing and facility disruptions, such as the impact of Hurricane Helene on the North Cove facility. Quality concerns are highlighted by voluntary corrections and ship-and-installation holds for the Novum IQ Large Volume Pump in the U.S. and Canada. Strategically, the company is integrating Hillrom and divesting its Kidney Care business (Vantive). Technological risks center on cybersecurity and the integration of AI/ML into product offerings. Globally, Baxter must navigate the EU Medical Device Regulation's 2028 compliance deadline, U.S. pharmaceutical "re-shoring" tariffs, and environmental restrictions on DEHP, PFAS, and desflurane. Labor stability is tied to collective bargaining agreements expiring in 2027 and 2029.
Feb 12, 2026	risk_factors	Baxter faces significant operational and financial headwinds, most notably the Class I recalls and subsequent ship-and-installation hold of the Novum LVP pump in the U.S. and Canada, which has triggered multiple class action and derivative lawsuits. Financial stability is pressured by substantial indebtedness and recent credit rating downgrades by S&P to BBB- and Moody’s to Baa3. Strategic volatility persists following the divestiture of the Kidney Care business and the integration of Hillrom, with the Front Line Care reporting unit recording significant goodwill impairments. Regulatory risks include ongoing DOJ and DHHS investigations into False Claims Act and Anti-Kickback Statute compliance related to Hillrom, as well as the ongoing costs of complying with European Medical Devices Regulations. Operational vulnerabilities are highlighted by the impact of Hurricane Helene on the North Cove facility and pending litigation regarding ethylene oxide exposure. Additionally, the company is exposed to pricing pressures, supply chain disruptions, and foreign currency volatility across its global markets. These factors, combined with the need to mitigate dis-synergies from the Kidney Care sale, constrain Baxter's ability to pursue growth strategies and advance R&D capabilities.

Filed

Item

Context

Feb 12, 2026

business

Baxter International Inc. provides essential healthcare products across three reportable segments: Medical Products & Therapies (sterile IV solutions, infusion systems, and parenteral nutrition), Healthcare Systems & Technologies (smart bed systems, patient monitoring, and respiratory devices), and Pharmaceuticals (specialty injectables and inhaled anesthetics). The company is currently executing a rigorous portfolio optimization and deleveraging strategy, evidenced by the divestitures of its BioPharma Solutions and Kidney Care businesses. Proceeds from these transactions were primarily used to retire legacy debt, as Baxter targets a net leverage ratio of approximately 3.0x by the end of 2026. To support this financial discipline, the company has reduced its dividend and suspended share repurchases. Strategically, Baxter is shifting toward "connected care" by integrating software and digital analytics into its device portfolio to improve patient outcomes. Operationally, the company has implemented a new operating model to streamline manufacturing and supply chains, reducing managerial layers and exploring AI-driven automation to increase efficiency. Baxter maintains a global footprint, selling in over 100 countries through direct sales and third-party distributors including Cardinal Health and Medline.

Feb 12, 2026

mda

Baxter faces potential material impairments to goodwill and intangible assets, particularly following the 2021 Hillrom acquisition. Revenue is heavily dependent on contracts with Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs), which often restrict pricing and include "failure to supply" penalties. Supply chain vulnerabilities persist due to reliance on sole-source providers for resins, electromechanical components, and active pharmaceutical ingredients. Operational risks include complex biologics manufacturing and facility disruptions, such as the impact of Hurricane Helene on the North Cove facility. Quality concerns are highlighted by voluntary corrections and ship-and-installation holds for the Novum IQ Large Volume Pump in the U.S. and Canada. Strategically, the company is integrating Hillrom and divesting its Kidney Care business (Vantive). Technological risks center on cybersecurity and the integration of AI/ML into product offerings. Globally, Baxter must navigate the EU Medical Device Regulation's 2028 compliance deadline, U.S. pharmaceutical "re-shoring" tariffs, and environmental restrictions on DEHP, PFAS, and desflurane. Labor stability is tied to collective bargaining agreements expiring in 2027 and 2029.

Feb 12, 2026

risk_factors

Baxter faces significant operational and financial headwinds, most notably the Class I recalls and subsequent ship-and-installation hold of the Novum LVP pump in the U.S. and Canada, which has triggered multiple class action and derivative lawsuits. Financial stability is pressured by substantial indebtedness and recent credit rating downgrades by S&P to BBB- and Moody’s to Baa3. Strategic volatility persists following the divestiture of the Kidney Care business and the integration of Hillrom, with the Front Line Care reporting unit recording significant goodwill impairments. Regulatory risks include ongoing DOJ and DHHS investigations into False Claims Act and Anti-Kickback Statute compliance related to Hillrom, as well as the ongoing costs of complying with European Medical Devices Regulations. Operational vulnerabilities are highlighted by the impact of Hurricane Helene on the North Cove facility and pending litigation regarding ethylene oxide exposure. Additionally, the company is exposed to pricing pressures, supply chain disruptions, and foreign currency volatility across its global markets. These factors, combined with the need to mitigate dis-synergies from the Kidney Care sale, constrain Baxter's ability to pursue growth strategies and advance R&D capabilities.

Forward Estimates

BAX filing events and research context

Keep researching BAX

Related tickers

Related explainers

Forward Estimates